Chronos Archive seal
The Human Record

Ann Richards

Case HR-ML019 · Modern EHR teaching episode · Draft for review

Review summary

Historical dates
September 1, 1933 – September 13, 2006
Synthetic DOB
1962-09-01
Index visit
2026-02-10 at age 63
Synthetic MRN
HR-ML019-SYN

Teaching objective: Evaluate bone health in a 63-year-old postmenopausal woman after a fall with a hand fracture: read the DXA T-scores precisely (low bone mass, not osteoporosis by T-score), calculate FRAX with her risk factors, and base the treatment decision on the guideline thresholds; complete a secondary-causes work-up and correct vitamin D before an antiresorptive; choose therapy strictly by guideline and her risk; add calcium, vitamin D, weight-bearing and balance exercise, and falls prevention; set the DXA follow-up interval and the drug-holiday reassessment; and give recovery-oriented care for an alcohol use disorder in long remission, with a structured safety assessment, on the CMID osteoporosis schedule.

Historical timeline

DateEventClaims
September 1, 1933Born Dorothy Ann Willis in Lakeview, near Waco, Texas.CLM-0001
1980Enters treatment for alcohol use and emerges sober.CLM-0003
1982Elected Texas state treasurer; keynote address at the 1988 Democratic National Convention; elected governor in 1990.CLM-0002
1996 (1994 in one source)Falls and breaks her hand; a bone density test shows osteopenia, described as early osteoporosis.CLM-0005, CLM-0006, CLM-0007
2003Publishes I'm Not Slowing Down: Winning My Battle with Osteoporosis; reports that her bone density has stabilized.CLM-0008, CLM-0009, CLM-0010
September 13, 2006Dies at home in Austin, six months after esophageal cancer was found.CLM-0011

Evidence claims

D = documented, R = retrospective, S = synthetic.

GradeClaimCertaintySources
D Ann Richards was born Dorothy Ann Willis on September 1, 1933, in Lakeview, near Waco, Texas. confirmed Ann Willis Richards (plot holder record) supports
Ann Richards (Research Starters biography) supports
D She was elected Texas state treasurer in 1982, gave the keynote address at the 1988 Democratic National Convention, was elected governor of Texas in 1990, and served one term after losing her bid for re-election in 1994.
Used for the synthetic modern occupation (public speaker and adviser).
confirmed Ann W. Richards (governor's biography) supports
Ann Richards dies at 73 (Associated Press) supports
D She spoke openly about her past heavy drinking ("I smoked like a chimney and drank like a fish"), entered treatment, and emerged sober; one biography dates the treatment to 1980 and describes it as successful.
Her own public account of alcohol use disorder and long recovery, and of past heavy smoking. Used for the synthetic problem of alcohol use disorder in sustained remission and for the former-smoker history; the quit date for tobacco is not documented.
confirmed Ann W. Richards (governor's biography) supports
Ann Richards (Research Starters biography) supports
D She said publicly that her mother had osteoporosis, broke "her arm, her hip," and developed a hump, and that osteoporosis was not the cause of her mother's death but led to it.
Her own public account of her mother's illness. Used for the family history and the parental hip fracture entered in FRAX.
confirmed Ann Richards on osteoporosis (CBS News report) supports
Morales T. Ann Richards' Latest Battle supports
D Because of her mother's fractures, she asked her doctor at an annual checkup to test her bone density.
Her own public account.
confirmed Ann Richards on osteoporosis (CBS News report) supports
Larry King Live transcript, May 14, 2002 supports
D She had a bone density test after falling and breaking her hand. CBS News (2003) and a publisher's summary date this to 1996, and CBS says she fell twice and broke her hand and her ankle; a Publishers Weekly review dates the hand fracture to 1994.
The hand fracture is consistent across sources; its year (1996 in two sources, 1994 in one) and the ankle fracture (one source) are not. The case uses a fall with a hand fracture the year before the index visit and records the ankle fracture as reported in one source.
probable Morales T. Ann Richards' Latest Battle supports
Winning My Battle with Osteoporosis (book description) supports
Review: I'm Not Slowing Down: Winning My Battle with Osteoporosis supports
D The bone density test showed osteopenia, which CBS News and the publisher's summary call an early stage of osteoporosis; in other interviews she said she had osteoporosis or early osteoporosis.
The published label is low bone mass (osteopenia), described as early osteoporosis. No source gives her T-scores; the synthetic T-scores stay in the low bone mass range.
confirmed Morales T. Ann Richards' Latest Battle supports
Winning My Battle with Osteoporosis (book description) supports
Review: I'm Not Slowing Down: Winning My Battle with Osteoporosis supports
Ann Richards on osteoporosis (CBS News report) supports
D CBS News reported in 2003 that she had shrunk three-quarters of an inch; in a 2002 television interview she said "my neck bones were collapsing and I literally was shrinking."
Lay description of height loss; no source reports a vertebral fracture. Used only for the measured height loss of about 2 cm in the synthetic examination.
probable Morales T. Ann Richards' Latest Battle supports
Larry King Live transcript, May 14, 2002 supports
D She took a prescription medicine, began weight-bearing exercise and weight training, and changed her diet; CBS News reported in 2003 that her bone density had stabilized, and that she was a spokesperson for the maker of the medicine she took.
Her public account of treatment. The product is not named in this record, and the synthetic treatment is chosen by guideline and her synthetic data, not by her real treatment.
confirmed Morales T. Ann Richards' Latest Battle supports
Review: I'm Not Slowing Down: Winning My Battle with Osteoporosis supports
Ann Richards on osteoporosis (CBS News report) supports
D In 2003 she published I'm Not Slowing Down: Winning My Battle with Osteoporosis, written with Richard U. Levine, MD, to encourage women and men to ask their doctors for a bone density test. confirmed Review: I'm Not Slowing Down: Winning My Battle with Osteoporosis supports
Winning My Battle with Osteoporosis (book description) supports
HISTMED Master Roster v3 supports
D She was found to have esophageal cancer in March 2006, received chemotherapy, and died at her home in Austin on September 13, 2006, at 73.
History only; after the true-frame episode and not used in it.
confirmed Ann Richards dies at 73 (Associated Press) supports
Ann Willis Richards (plot holder record) supports
Ann Richards (Research Starters biography) supports

Modern synthetic problem list

GradeProblemClinical statusVerificationPlacementHistorical claims
S Low bone mass (osteopenia) of the lumbar spine and hip on DXA, lowest T-score -2.3 at the lumbar spine (femoral neck -2.0, total hip -1.7), with a 10-year FRAX risk above the treatment thresholds (major osteoporotic fracture 22 percent, hip 3.6 percent); not osteoporosis by T-score, but meets the AACE 2020 clinical criteria for osteoporosis (low bone mass with a FRAX risk above threshold) active confirmed both_with_link CLM-0005, CLM-0006, CLM-0007, CLM-0004
S Alcohol use disorder in sustained remission for more than fifteen years, since treatment; no alcohol since active confirmed both_with_link CLM-0003
S History of falls: a fall from standing height with a hand fracture last year (and, in one account, a second fall with an ankle fracture); no falls since active confirmed both_with_link CLM-0006

Synthetic outcome measures

GradeDateMeasureResultCoding
S 2026-02-10 DXA Lumbar spine [T-score] Bone density -2.3 (low)
Reference -1.0 or higher is normal; between -1.0 and -2.5 is low bone mass (osteopenia); -2.5 or lower is osteoporosis
http://loinc.org · 38267-1
S 2026-02-10 DXA Femur [T-score] Bone density -2 (low)
Reference -1.0 or higher is normal; between -1.0 and -2.5 is low bone mass (osteopenia); -2.5 or lower is osteoporosis
http://loinc.org · 38263-0
S 2026-02-10 DXA Hip [T-score] Bone density -1.7 (low)
Reference -1.0 or higher is normal; between -1.0 and -2.5 is low bone mass (osteopenia); -2.5 or lower is osteoporosis
http://loinc.org · 38264-8
S 2026-02-10 Major osteoporotic fracture 10-year probability [Likelihood] Fracture Risk Assessment 22% http://loinc.org · 90265-0
S 2026-02-10 Hip fracture 10-year probability [Likelihood] Fracture Risk Assessment 3.6% http://loinc.org · 90266-8
S 2026-02-10 Calcium [Mass/volume] in Serum or Plasma 9.4 mg/dL
Reference 8.6-10.3 mg/dL
http://loinc.org · 17861-6
S 2026-02-10 Albumin [Mass/volume] in Serum or Plasma 4.2 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-02-10 Creatinine [Mass/volume] in Serum or Plasma 0.8 mg/dL
Reference 0.5-1 mg/dL
http://loinc.org · 2160-0
S 2026-02-10 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 81 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-02-10 Phosphate [Mass/volume] in Serum or Plasma 3.5 mg/dL
Reference 2.5-4.5 mg/dL
http://loinc.org · 2777-1
S 2026-02-10 Magnesium [Mass/volume] in Serum or Plasma 2 mg/dL
Reference 1.7-2.4 mg/dL
http://loinc.org · 19123-9
S 2026-02-10 Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 84 U/L
Reference 40-120 U/L
http://loinc.org · 6768-6
S 2026-02-10 Parathyrin.intact [Mass/volume] in Serum or Plasma 54 pg/mL
Reference 15-65 pg/mL
http://loinc.org · 2731-8
S 2026-02-10 Thyrotropin [Units/volume] in Serum or Plasma 1.9 mIU/L
Reference 0.4-4 mIU/L
http://loinc.org · 3016-3
S 2026-02-10 Hemoglobin [Mass/volume] in Blood 13.3 g/dL
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-02-10 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 21 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 2026-02-10 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 24 ng/mL (low)
Reference Target 30 ng/mL or higher before and during osteoporosis treatment
http://loinc.org · 62292-8
S 2026-02-10 Collagen crosslinked C-telopeptide [Mass/volume] in Serum or Plasma 560 pg/mL
Reference Postmenopausal reference interval 104 to 1008 pg/mL; a fall of more than about 30 percent on antiresorptive therapy indicates response
http://loinc.org · 41171-0
S 2026-02-10 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 2 http://loinc.org · 44261-6
S 2026-02-10 Total score [AUDIT-C] 0 http://loinc.org · 75626-2
S 2026-05-12 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 38 ng/mL
Reference Target 30 ng/mL or higher before and during osteoporosis treatment
http://loinc.org · 62292-8
S 2026-05-12 Calcium [Mass/volume] in Serum or Plasma 9.5 mg/dL
Reference 8.6-10.3 mg/dL
http://loinc.org · 17861-6
S 2026-05-12 Creatinine [Mass/volume] in Serum or Plasma 0.8 mg/dL
Reference 0.5-1 mg/dL
http://loinc.org · 2160-0
S 2026-05-12 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 81 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-05-12 Calcium [Mass/time] in 24 hour Urine 172 mg/(24.h)
Reference 100-300 mg/(24.h)
http://loinc.org · 6874-2
S 2026-08-11 Collagen crosslinked C-telopeptide [Mass/volume] in Serum or Plasma 190 pg/mL
Reference Postmenopausal reference interval 104 to 1008 pg/mL; a fall of more than about 30 percent on antiresorptive therapy indicates response
http://loinc.org · 41171-0
S 2026-08-11 Calcium [Mass/volume] in Serum or Plasma 9.3 mg/dL
Reference 8.6-10.3 mg/dL
http://loinc.org · 17861-6
S 2026-10-06 Cholesterol [Mass/volume] in Serum or Plasma 204 mg/dL (high)
Reference <=199 mg/dL
http://loinc.org · 2093-3
S 2026-10-06 Cholesterol in HDL [Mass/volume] in Serum or Plasma 62 mg/dL
Reference >=50 mg/dL
http://loinc.org · 2085-9
S 2026-10-06 Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 118 mg/dL
Reference <=129 mg/dL
http://loinc.org · 13457-7
S 2026-10-06 Triglyceride [Mass/volume] in Serum or Plasma 120 mg/dL
Reference <=149 mg/dL
http://loinc.org · 2571-8
S 2026-10-06 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 http://loinc.org · 55758-7
S 2026-10-06 Total score [AUDIT-C] 0 http://loinc.org · 75626-2

Synthetic vital signs

DateMeasureResultLOINCGrade
2026-02-10Body height164 cm8302-2S
2026-02-10Body weight66 kg29463-7S
2026-02-10Body mass index (BMI) [Ratio]24.5 kg/m239156-5S
2026-02-10Systolic blood pressure124 mm[Hg]8480-6S
2026-02-10Diastolic blood pressure76 mm[Hg]8462-4S
2026-02-10Heart rate72 /min8867-4S
2026-02-10Respiratory rate14 /min9279-1S
2026-02-10Body temperature36.6 Cel8310-5S
2026-02-10Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-03-10Body height164 cm8302-2S
2026-03-10Body weight66.2 kg29463-7S
2026-03-10Body mass index (BMI) [Ratio]24.6 kg/m239156-5S
2026-03-10Systolic blood pressure122 mm[Hg]8480-6S
2026-03-10Diastolic blood pressure74 mm[Hg]8462-4S
2026-03-10Heart rate70 /min8867-4S
2026-03-10Respiratory rate14 /min9279-1S
2026-03-10Body temperature36.7 Cel8310-5S
2026-03-10Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-05-12Body height164 cm8302-2S
2026-05-12Body weight66.4 kg29463-7S
2026-05-12Body mass index (BMI) [Ratio]24.7 kg/m239156-5S
2026-05-12Systolic blood pressure120 mm[Hg]8480-6S
2026-05-12Diastolic blood pressure74 mm[Hg]8462-4S
2026-05-12Heart rate72 /min8867-4S
2026-05-12Respiratory rate14 /min9279-1S
2026-05-12Body temperature36.6 Cel8310-5S
2026-05-12Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-08-11Body height164 cm8302-2S
2026-08-11Body weight66 kg29463-7S
2026-08-11Body mass index (BMI) [Ratio]24.5 kg/m239156-5S
2026-08-11Systolic blood pressure122 mm[Hg]8480-6S
2026-08-11Diastolic blood pressure76 mm[Hg]8462-4S
2026-08-11Heart rate68 /min8867-4S
2026-08-11Respiratory rate14 /min9279-1S
2026-08-11Body temperature36.7 Cel8310-5S
2026-08-11Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-10-06Body height164 cm8302-2S
2026-10-06Body weight65.8 kg29463-7S
2026-10-06Body mass index (BMI) [Ratio]24.5 kg/m239156-5S
2026-10-06Systolic blood pressure122 mm[Hg]8480-6S
2026-10-06Diastolic blood pressure74 mm[Hg]8462-4S
2026-10-06Heart rate70 /min8867-4S
2026-10-06Respiratory rate14 /min9279-1S
2026-10-06Body temperature36.6 Cel8310-5S
2026-10-06Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S

Social, functional, and mental status

Social history

Functional status

Mental status

Structured safety assessment

Current ideation
absent
Intent
absent
Plan
absent
Disposition
Routine outpatient care. Crisis resources, including the 988 Suicide & Crisis Lifeline, given in writing and saved in her phone; safety reviewed at each visit

This assessment is synthetic and does not convert historical behavior into a present-day fact.

Allergies and medications

Allergies

Medications

Procedures and immunizations

Procedures

Immunizations

Past medical history

True biography with historical dates; not part of the synthetic care timeline.

Family history

Care-plan goals

GoalTarget dateStatusOutcome
Total calcium intake of about 1200 mg a day, mostly from food, by the four-week visit2026-03-10completedAbout 1200 mg a day from food by her own three-day food record
25-hydroxyvitamin D of 30 ng/mL or more before the first infusion2026-05-12completed24 ng/mL at intake and 38 ng/mL at three months
First zoledronic acid dose by the three-month visit, with normal calcium and kidney function and a dental check done2026-05-12completedGiven at three months after normal calcium (9.5 mg/dL) and eGFR (81) and a routine dental examination
Complete the eight-week balance and strength program, with no falls through six months2026-08-11completed16 of 16 sessions; Timed Up and Go 9 seconds and tandem stance 20 seconds at six months; no falls
Serum CTX at least 30 percent lower three months after the first dose2026-08-11completed560 pg/mL at baseline and 190 pg/mL at three months after the dose (66 percent lower)
Sustained remission from alcohol use disorder throughout the episode2026-08-11completedNo alcohol reported at any visit; AUDIT-C 0 at intake

Interventions

InterventionStatusGuideline
Endocrinology consultation to confirm the diagnostic category from the T-scores and FRAX, the risk category, the choice of drug, the secondary-causes work-up, and the plan for monitoring and treatment durationcompletedGL-CMID-2026, GL-BHOF-2022, GL-AACE-2020, GL-ENDO-2019
Drug treatment, because FRAX is above the treatment thresholds, with the agent confirmed at the endocrinology visit: zoledronic acid 5 mg intravenously once a year, given only after 25-hydroxyvitamin D is 30 ng/mL or more, calcium is normal, eGFR is above 35, and a routine dental examination is done; acetaminophen for the expected aches and fever after the first dose; reassess after three yearly doses for a drug holidaycompletedGL-CMID-2026, GL-BHOF-2022, GL-AACE-2020, GL-ENDO-2019, GL-ENDO-2020
Calcium about 1200 mg a day in total, from food first, and vitamin D3 2000 units a day to reach 30 ng/mL or more, then continue; caffeine kept to two cups of coffee a day; no tobacco or alcoholcompletedGL-CMID-2026, GL-BHOF-2022, GL-AACE-2020
Falls prevention by CDC STEADI: supervised balance and strength exercise with a physical therapist for eight weeks, then a home program three times a week; weight-bearing exercise most days; home safety review (stair rails, night lights, no loose rugs); low-heeled shoes when traveling; yearly vision checkcompletedGL-CDC-STEADI, GL-USPSTF-FALLS-2024, GL-BHOF-2022
Monitoring on the CMID osteoporosis schedule: secondary-causes tests at baseline (calcium, albumin, phosphate, magnesium, alkaline phosphatase, creatinine and eGFR, PTH, 25-hydroxyvitamin D, TSH, blood count, and 24-hour urine calcium); calcium and creatinine before each infusion; fasting CTX at baseline and three to six months after starting; 25-hydroxyvitamin D after repletion and then yearly; height and fall-risk screen yearly; FRAX recalculated when risk factors change; DXA of the spine and hip two years after starting, on the same scannercompletedGL-CMID-2026, GL-AACE-2020, GL-ENDO-2019, GL-USPSTF-OSTEO-2025
Recovery-oriented care for alcohol use disorder in sustained remission: ask about alcohol, cravings, and stress at each visit in a non-judgmental way, support the recovery practices she uses, avoid sedating medicines, and review safety with the 988 Suicide & Crisis Lifeline at each visitcompletedGL-SUD-2021, GL-SUICIDE-2024, GL-CMID-2026

Planned encounters

Supporting documents

C-CDA note documents

Each link opens a readable copy; the XML beside it is the exchange file.

Sources

IDSourcePublisherType
SRC-0001 Morales T. Ann Richards' Latest Battle CBS News other
SRC-0002 Ann Richards on osteoporosis (CBS News report) CBS News other
SRC-0003 Larry King Live transcript, May 14, 2002 CNN other
SRC-0004 Review: I'm Not Slowing Down: Winning My Battle with Osteoporosis Publishers Weekly other
SRC-0005 Winning My Battle with Osteoporosis (book description) Texas Cooking other
SRC-0006 Ann W. Richards (governor's biography) Texas State Library and Archives Commission government
SRC-0007 Ann Richards (Research Starters biography) EBSCO biography
SRC-0008 Ann Willis Richards (plot holder record) Texas State Cemetery government
SRC-0009 Ann Richards dies at 73 (Associated Press) The Spokesman-Review other
SRC-0010 HISTMED Master Roster v3 The Human Record project other

Review status

ReviewStatusNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the T-score and FRAX reading (low bone mass with FRAX above threshold, and entering the hand fracture as a previous fracture), the AACE risk category, the drug choice, and the deviation recorded for the late 24-hour urine calcium.
provenance reviewnot_startedRecent-death rule: only what Richards made public (her book, interviews, and press coverage) and basic biographical facts are used. Her real T-scores were not found and are not used; her real medicine is not named, and no promotional claim is repeated. The fracture year conflict (1996 or 1994) is recorded.
safe messaging reviewnot_startedAlcohol and tobacco claims are marked sensitive; recovery is described in person-first, non-stigmatizing language; the safety assessment records no current risk and gives the 988 Suicide & Crisis Lifeline; her later cancer and death are recorded as history only, without detail.

Comments and corrections

Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.

Comments appear on the online version of this page.